Paris, November 30 (ots/PRNewswire) – – First New Anti-Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the European Commission has granted marketing authorization for Multaq(R) (dronedarone – 400mg Tablets) in all 27 European member states. This approval follows the European [...]
Tag Archive > Treatment Approach
Innovative Treatment Approach Offers New Hope for Eczema Sufferers With Moderate to Severe Disease PROTOPIC(R)
Prague (ots/PRNewswire) – – Ointment (Tacrolimus Monohydrate) in a New Twice-Weekly Regimen can Help Prevent Eczema Flares Today sees the European launch of the first topical calcineurin inhibitor to be approved for the maintenance treatment of eczema to prevent flares and prolong flare-free intervals. PROTOPIC ointment (tacrolimus monohydrate) is already licensed to treat moderate and [...]
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Zug, Switzerland (ots/PRNewswire) – – First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen (Nasdaq: AMGN) today announced that the European Commission (EC) has granted marketing authorisation for Nplate(R) (romiplostim) for the treatment of splenectomised adult chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients who are refractory [...]
Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
Thousand Oaks, California, November 21 (ots/PRNewswire) – – First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen (Nasdaq: AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for Nplate(TM) (romiplostim) in the European Union (EU). [...]
